Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ACA, accidental, Activyl, Afferent, allogeneic, altrenogest, Aquavac, Aralez, argument, Atozet, attached, Avirulent, background, Bacterin, baterin, bench, Betamethasone, bill, Biopharma, Cabilly, carboplatin, carcinoma, CDI, CENCOEX, clarified, clarify, classical, cleaving, cloprostenol, Clotrimazole, CMS, CMV, Cogan, declaratory, degradation, DICOM, DIPRO, earliest, eDMC, element, Emamectin, entail, fenbendazole, florfenicol, flunixin, Genentech, Gentamicin, Gilead, graduated, Green, Harvoni, hepatocellular, HNSCC, Hodgkin, Hope, HTA, Hyopneumoniae, idiopathic, impracticable, inactive, India, ineligible, kind, Lancet, Lawsonia, learned, lease, legislature, Levitra, licensor, lovastatin, Magistrate, Marek, Marrow, MCM, mediastinal, meglumine, messenger, Mexico, Misuse, Moderna, Mountain, multicenter, Mycoplasma, nasopharyngeal, NAV, neurogenic, norfloxacin, Northern, Ohio, Orbifloxacin, Otic, Otomax, overturn, page, Panacur, payer, PDL, pemetrexed, porcine, pre, PRIME, PTE, qui, reallocate, recast, reconciling, refractory, relapsed, repeal, Roxane, ruzasvir, score, simplify, sofosbuvir, Solvadi, spanning, SPC, StayWell, steadily, stem, student, substitute, sulfate, suppression, tam, Tildipirosin, TPS, transparency, trenbolone, unsuccessful, untreated, uprifosbuvir, urothelial, USP, valerate, Vector, Vermont, Vestar, visit, voted, withheld, zilpaterol, zinc, Zinplava
Removed:
acid, affirming, aggressively, agree, alfa, allegedly, announce, answered, antihistamine, API, approving, Aspen, assisted, atherothrombotic, Austria, BACE, Bank, base, Basic, Becton, begun, Belgium, blockade, Brazilian, break, bulk, call, capped, CDC, certiorari, Clarinex, community, confident, Congressional, constipation, Conversely, corifollitropin, coronary, Cosopt, DEESE, density, desloratadine, devalued, Dickinson, dipeptidyl, Dodge, downplayed, Dr, economically, Eldon, elevated, enable, enactment, enhance, entirety, Eurofarma, evolution, exclusively, exhausted, failed, Fallon, feed, finalized, finasteride, fiscal, formula, Fort, Fosavance, FTC, function, Gleeson, hair, home, hormonal, incremental, induced, Inhibition, injunction, inspection, internationally, investor, ipilimumab, John, joined, lesser, lieu, Louisiana, lump, manner, minimize, Ministry, Missouri, morbidity, mortality, move, Mylan, nonforfeitable, Obama, obesity, offshore, oversaw, Parenteral, pattern, PF, Pisano, placebo, Portugal, posed, predetermined, predicting, prefilled, preladenant, presenting, prevented, prioritization, protease, rapidly, remanded, remeasurement, repricing, reproductive, retainer, retired, retroactively, revocation, rheumatoid, rocuronium, rosenblatt, routinely, Sandoz, selectively, sharpen, SICAD, similarly, Spanish, specialty, stay, stimulation, Supreme, Sweden, syringe, Taxpayer, territorial, thromboembolism, tildrakizumab, triple, Trusopt, uncured, undertaken, unrepatriated, utilize, vacated, vecuronium, venued, view, voice, voluntary, VTE, waive, WILLIE, withdrawal, withdrew, Wyeth
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2 Exhibit 10.2: Deferral Program Document (Amended & Restated 12/1/15)
- 10.19 Exhibit 10.19: 2016 Nqso Grants Under Merck & Co., Inc. 2010 Incentive Stock PLN
- 10.20 Exhibit 10.20: 2016 Rsu Grants Under Merck & Co., Inc. Incentive Stock Plan
- 10.21 Exhibit 10.21: 2016 Psu Award Terms Under Merck & Co., Inc. 2010 Stock Incentive
- 10.24 Exhibit 10.24: Merck & Co., Inc. U.S. Separation Benefits Plan Eff 01/01/17
- 12 Exhibit 12: Computation of Ratios of Earnings to Fixed Charges
- 21 Exhibit 21: Subsidiary List
- 23 Exhibit 23: Consent of Independent Registered Public Accounting Firm
- 24.1 Exhibit 24.1: Power of Attorney
- 24.2 Exhibit 24.2: Certification of Board Resolution
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 12
MERCK & CO., INC. AND SUBSIDIARIES
Computation of Ratios of Earnings to Fixed Charges
($ in millions except ratio data)
Years Ended December 31, | |||||||||||||||||||
2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||
Income Before Taxes | $ | 4,659 | $ | 5,401 | $ | 17,283 | $ | 5,545 | $ | 8,739 | |||||||||
Add (Subtract): | |||||||||||||||||||
One-third of rents | 97 | 101 | 117 | 122 | 133 | ||||||||||||||
Interest expense, gross | 693 | 672 | 732 | 801 | 714 | ||||||||||||||
Interest capitalized, net of amortization | — | (3) | (1) | (2) | (49) | ||||||||||||||
Equity (income) loss from affiliates, net of distributions | (70) | (155) | (72) | (168) | (350) | ||||||||||||||
Earnings as defined | $ | 5,379 | $ | 6,016 | $ | 18,059 | $ | 6,298 | $ | 9,187 | |||||||||
One-third of rents | $ | 97 | $ | 101 | $ | 117 | $ | 122 | $ | 133 | |||||||||
Interest expense, gross | 693 | 672 | 732 | 801 | 714 | ||||||||||||||
Preferred stock dividends | — | — | 86 | 147 | 163 | ||||||||||||||
Fixed Charges | $ | 790 | $ | 773 | $ | 935 | $ | 1,070 | $ | 1,010 | |||||||||
Ratio of Earnings to Fixed Charges | 7 | 8 | 19 | 6 | 9 |
For purposes of computing these ratios, “earnings” consist of income before taxes, one-third of rents (deemed by the Company to be representative of the interest factor inherent in rents), interest expense, interest capitalized, net of amortization and equity (income) loss from affiliates, net of distributions. “Fixed charges” consist of one-third of rents, interest expense as reported in the consolidated financial statements and dividends on preferred stock. Interest expense does not include interest related to uncertain tax positions.